Compare · CYRX vs LLY
CYRX vs LLY
Side-by-side comparison of CryoPort Inc. (CYRX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CYRX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.08T, about 1422.5x CYRX ($760.6M).
- Over the past year, CYRX is up 106.9% and LLY is up 50.8% - CYRX leads by 56.2 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 1 for CYRX).
- Both have 25 recent analyst ratings on file.
- Company
- CryoPort Inc.
- Eli Lilly and Company
- Price
- $15.04-1.80%
- $1148.86-0.60%
- Market cap
- $760.6M
- $1.08T
- 1M return
- -5.14%
- -3.63%
- 1Y return
- +106.95%
- +50.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 11
- Recent ratings
- 25
- 25
CryoPort Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities are maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CYRX
- Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026
- Cryoport's IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs
- SEC Form S-8 filed by CryoPort Inc.
- SEC Form 15-12G filed by CryoPort Inc.
- Chief Digital and Tech Officer Zecchini Edward J exercised 35,000 shares at a strike of $4.80 and sold $507,563 worth of shares (35,000 units at $14.50) (SEC Form 4)
- CryoPort Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Baddour Linda was granted 10,350 shares, increasing direct ownership by 18% to 68,099 units (SEC Form 4)
- Chief Financial Officer Stefanovich Robert sold $2,756,984 worth of shares (169,427 units at $16.27), decreasing direct ownership by 61% to 109,850 units (SEC Form 4)
- Director Hancock Daniel M was granted 10,350 shares, increasing direct ownership by 18% to 69,052 units (SEC Form 4)
- Director Hariri Robert J was granted 10,350 shares, increasing direct ownership by 20% to 61,625 units (SEC Form 4)
Latest LLY
- New insider Eli Lilly & Co claimed ownership of 1,054,828 shares (SEC Form 3)
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
- Lilly confirms date and conference call for second-quarter 2026 financial results announcement
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,000 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,905 units (SEC Form 4)
- Director Fyrwald J Erik was granted 9 shares, increasing direct ownership by 0.01% to 75,410 units (SEC Form 4)
- Director Alvarez Ralph was granted 11 shares, increasing direct ownership by 0.02% to 55,734 units (SEC Form 4)
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions